- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03477279
Developing and Assessing a Male Engagement Intervention in Option B+ in Malawi
Developing and Assessing a Male Engagement Intervention in Option B+ in Malawi: A Randomized Controlled Trial in Lilongwe
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
In sub-Saharan Africa, engaging HIV-infected men in HIV care and treatment and engaging HIV-uninfected men in prevention has proven challenging. Along all steps of the HIV care-seeking cascade, men exhibit worse care-seeking behaviors. They are less likely to seek HIV testing and counseling (HTC), initiate combination antiretroviral therapy (cART), and be retained in cART care. Poor care-seeking has resulted in a lower prevalence of viral suppression and earlier mortality. Additionally, men rarely engage in the antenatal care-seeking of their female sexual partners, leading to worse maternal and infant outcomes. This low level of engagement has been noted in Malawi's Option B+ prevention of mother to child transmission (PMTCT) program, and has been a critical barrier to female Option B+ uptake and retention, and a missed opportunity for engaging men.
There is promising evidence that couple-based approaches within Malawi's Option B+ prevention of mother to child transmission program could address all of these challenges: poor male engagement in the HIV continuum of care, low male adoption of biomedical HIV prevention approaches, sub-optimal female engagement in the continuum of care, and poor or uncertain infant outcomes. Our team has designed a couples-based intervention to address these challenges, and will conduct a randomized controlled trial (N=500 couples) to assess intervention effectiveness at one year. Results from this study are expected to inform how best to address family outcomes in an Option B+ program.
This study has the following aims described below:
Aim 1: Determine whether the couple-based intervention increases new HIV-positive diagnoses among HIV-infected male sex partners, helps HIV-infected men engage and remain in care, and contributes to male viral suppression compared to individual standard of care. The investigators will compare the couple-based intervention to standard of care for increasing the proportion of men who are aware of being HIV-infected, the proportion of these men who initiate and remain in cART care, and the proportion of these men with viral suppression at one year.
Aim 2: Determine whether the couple-based intervention identifies HIV-discordant couples and decreases the likelihood of male exposure to HIV compared to individual standard of care. The investigators will compare the intervention to standard of care for increasing the number of men with non-HIV exposure from their female partner through consistent condom use, viral suppression, abstinence, or a combination of these methods over one year.
Aim 3: Determine whether the couple-based intervention improves female cART retention and viral suppression compared to individual standard of care. The investigators will compare the intervention to standard of care for female cART retention and viral suppression at one year.
Aim 4: Determine whether the couple-based intervention improves infant early infant diagnosis uptake compared to individual standard of care. Explore uptake of early infant diagnosis and rates of mother-to-child transmission and child survival in the two intervention arms.
Aim 5: Develop an in-depth understanding of HIV transmission dynamics in Lilongwe. Using the biomarkers and behavioral survey, we will seek to understand transmission timing, direction, and context in Lilongwe. We will compare women with recent HIV infection to a population of HIV-uninfected controls (n=350) to understand predictors of HIV acquisition in pregnancy in Malawi.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Central District
-
Lilongwe, Central District, Malaui
- Bwaila District Hospital Antenatal Unit
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria (HIV-infected Women):
- HIV-infected and eligible for Option B+
- >18 years old or 15-17 years old and married
- Planning to remain in the Bwaila catchment area for the next year or notify the study team if they leave the area or change facilities
Part of a heterosexual relationship for >3 months
- Expects the partner to be in the relevant catchment area for at least one week in the next six months.
- Able and willing to give locator information for this partner
- Willing to have study staff conduct phone and physical tracing of that partner
- Willing to undergo a couple-based intervention with this partner
- Able and willing to provide informed consent
Inclusion Criteria (Male Partners of HIV-infected women)
- >18 years old or 15-17 years old and married
In a relationship with the female partner for >3 months
- Willing to undergo a couples-based intervention with their female partner
- Able and willing to provide informed consent
Inclusion Criteria (HIV-uninfected Women):
- HIV-uninfected
- >18 years old or 15-17 years old and married
Part of a heterosexual relationship for >3 months
- Expects the partner to be in the relevant catchment area for at least one week in the next six months.
- Willing to receive couples-based HIV testing and counseling with this partner
- Able and willing to provide informed consent
Exclusion Criteria (all Women and Male Partners):
• Any condition that in the opinion of the study investigator would compromise the ability of the prospective participant to provide informed consent, undergo study procedures safely, or would prevent proper conduct of the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Sin intervención: Individual (SOC)
HIV-infected pregnant women enrolled in the individual arm of the study will receive Standard of Care Option B+ procedures.
|
|
Experimental: Couple (Intervention)
In addition to receiving standard of care procedures, HIV-infected pregnant women in the couple arm will be provided with an intervention aimed at recruiting their male partners, providing enhanced couple counseling and testing, engaging their male partners in their care, and supporting male partners to receive care and treatment services.
|
Participants are provided study-specific partner referral cards and encouraged to bring male partners to antenatal care for a male engagement intervention. Those who do not present on their own are then traced. Couples will receive three enhanced couple counseling sessions that include: pre-test counseling, return of joint results, and post-test counseling. HIV-infected men will be able to initiate cART at the antenatal clinic and the couple will be offered condoms from the HTC counselor. Between sessions, couple members can pick up condoms and cART for one another.
Otros nombres:
|
Sin intervención: HIV-Uninfected Cohort
HIV-uninfected pregnant women will be invited to participate in a cross-sectional study.
No intervention will be provided and no follow-up will be conducted.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Women Retained in Care
Periodo de tiempo: 12 months
|
Women who presented at 12 months and reported taking at least one dose of ART in the last seven days
|
12 months
|
Number of Women With Viral Suppression
Periodo de tiempo: 12 months
|
Women who presented at 12 months with a viral load <1000 copies/mL
|
12 months
|
Number of HIV-positive Male Partners Aware of Their HIV-positive Status
Periodo de tiempo: 12 months
|
HIV-positive male partners who presented at 12 months and reported knowing they were HIV-positive prior to receiving the results of the HIV test conducted at the 12 month study visit
|
12 months
|
Number of HIV-positive Male Partners Retained in Care
Periodo de tiempo: 12 months
|
HIV-positive male partners who presented at 12 months and reported taking at least one dose of ART in the last seven days
|
12 months
|
Number of HIV-positive Male Partners With Viral Suppression
Periodo de tiempo: 12 months
|
HIV-positive male partners who presented at 12 months with a viral load <1000 copies/mL
|
12 months
|
Number of HIV-negative Men Without HIV Exposure From Their Primary Partner
Periodo de tiempo: 12 months
|
HIV-negative men with a) consistent condom use in the last six months or b) a suppressed female partner or c) abstinence with primary partner
|
12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of HIV-positive Female Participants Who Reported Early Infant Diagnosis
Periodo de tiempo: 12 months
|
HIV-positive female participants who reported a live birth and uptake of early infant diagnosis
|
12 months
|
Predictors of Recent HIV Infection
Periodo de tiempo: At the day of female consent
|
Risk factor analysis to identify predictors of recent HIV infection among pregnant women
|
At the day of female consent
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Nora E Rosenberg, PhD, University of North Carolina, Chapel Hill
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- 17-0681
- R00MH104154 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre VIH
-
Icahn School of Medicine at Mount SinaiIRRASReclutamientoHemorragia Intraventricular (HIV)Estados Unidos
-
Yale UniversityTerminadoPrecocidad | Recién nacidos de muy bajo peso al nacer | Hemorragia Intraventricular (HIV) | Sangrado en el cerebroEstados Unidos
-
China Medical University HospitalDesconocidoDisplasia broncopulmonar | Bebés extremadamente prematuros | TLP grave que las terapias convencionales han fallado | Sin anomalías congénitas graves | no Hiv Severa Ni FPV QuísticaTaiwán